|Articles|April 25, 2020

The ID Pipeline: FDA Activity From the Week of April 19, 2020

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of April 19, 2020.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of April 19, 2020.

FDA Approves Sanofi's Quadrivalent Meningococcal Vaccine

The US Food and Drug Administration has approved a biologic license application for MenQuadfi meningococcal (Groups A, C, Y, W) conjugate vaccine. The approval was granted to Sanofi for the prevention of invasive meningococcal disease in persons 2 years and older.

MenQuadfi is the only FDA approved quadrivalent meningococcal vaccine that is indicated for individuals 2 through 56 years of age and older.

Read the full article.

FDA Grants EUA to LabCorp's At-Home COVID-19 Test Kit

The US Food and Drug Administration (FDA) has issued an emergency use authorization to LabCorp for at-home coronavirus disease 2019 (COVID-19) tests kits.

Under this authorization, nasal swab specimens can be collected at home using the Pixel by LabCorp COVID-19 collection kit. A health care provider must recommend the test and patients must complete a COVID-19 questionnaire prior to testing.

Read the full article.


Related to this article

Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.